GENFIT

Belkins
GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

XYLYX BIO PARTNERS WITH INVENTIA LIFE SCIENCE TO DEVELOP TISSUE-SPECIFIC, DIGITALLY-PRINTED BIOINKS FOR DRUG DISCOVERY

Xylyx Bio, Inc. | September 02, 2021

news image

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop...

Read More

AI

WHITELAB GENOMICS AND THE ACCELERATOR FOR TECHNOLOGICAL RESEARCH IN GENOMIC THERAPIES COLLABORATE ON AI FOR GENE THERAPY BIOPRODUCTION

WhiteLab Genomics | June 01, 2021

news image

As part of this collaboration, teams from the Accelerator for Technological Research in Genomic Therapies (ART-TG, Inserm US35) and WhiteLab Genomics will use the WhiteLab Genomics CatalystTM platform to generate a database specific to the bioproduction of lentiviral vectors, which will be used to identify the parameters allowing for a significant increase in vector quality as well as their production yields, and to reduce the production costs. Cell and gene therapy is a new biome...

Read More

MEDTECH

SORRENTO ANNOUNCES COVISTIX COVID-19 VIRUS RAPID ANTIGEN DETECTION TEST DETECTS THE OMICRON VARIANT

Sorrento Therapeutics, Inc. | December 28, 2021

news image

Sorrento Therapeutics, Inc. announced that initial testing of COVISTIX on recombinant N proteins demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and its other major VoCs such as the delta and delta-plus strains. The COVISTIX detection levels were similar for all variants. The ease of use and timely detection of Omicron infection was demonstrated by a recent case report of a Mexico patient infected with the Omicron variant detected fi...

Read More

MEDTECH

OCHRE BIO ENTERS INTO CHARITABLE DONATION AGREEMENT WITH BRITISH LIVER TRUST

Ochre Bio | December 15, 2021

news image

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effe...

Read More
news image

CELL AND GENE THERAPY

XYLYX BIO PARTNERS WITH INVENTIA LIFE SCIENCE TO DEVELOP TISSUE-SPECIFIC, DIGITALLY-PRINTED BIOINKS FOR DRUG DISCOVERY

Xylyx Bio, Inc. | September 02, 2021

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop...

Read More
news image

AI

WHITELAB GENOMICS AND THE ACCELERATOR FOR TECHNOLOGICAL RESEARCH IN GENOMIC THERAPIES COLLABORATE ON AI FOR GENE THERAPY BIOPRODUCTION

WhiteLab Genomics | June 01, 2021

As part of this collaboration, teams from the Accelerator for Technological Research in Genomic Therapies (ART-TG, Inserm US35) and WhiteLab Genomics will use the WhiteLab Genomics CatalystTM platform to generate a database specific to the bioproduction of lentiviral vectors, which will be used to identify the parameters allowing for a significant increase in vector quality as well as their production yields, and to reduce the production costs. Cell and gene therapy is a new biome...

Read More
news image

MEDTECH

SORRENTO ANNOUNCES COVISTIX COVID-19 VIRUS RAPID ANTIGEN DETECTION TEST DETECTS THE OMICRON VARIANT

Sorrento Therapeutics, Inc. | December 28, 2021

Sorrento Therapeutics, Inc. announced that initial testing of COVISTIX on recombinant N proteins demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and its other major VoCs such as the delta and delta-plus strains. The COVISTIX detection levels were similar for all variants. The ease of use and timely detection of Omicron infection was demonstrated by a recent case report of a Mexico patient infected with the Omicron variant detected fi...

Read More
news image

MEDTECH

OCHRE BIO ENTERS INTO CHARITABLE DONATION AGREEMENT WITH BRITISH LIVER TRUST

Ochre Bio | December 15, 2021

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health. “On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effe...

Read More